Quantitative liquid chromatographic determination of intact cisplatin in blood with microwave-assisted post-column derivatization and UV detection

Pierre, Pernilla Videhult; Wallin, Inger; Eksborg, Staffan; Ehrsson, Hans

doi:10.1016/j.jpba.2011.04.028

Cited by 14 publications

(9 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These monomers are incorporated into physiological processes at the cell level, where degradation proceeds, leading to the metabolic route, which can undergo chain disruption in the human body and degrades into non-toxic byproducts (i.e., lactic acid, carbon dioxide, and water), which are subsequently eliminated through the Krebs cycle and in the urine [21,22]. CDDP, which is a water-soluble low molecular weight, is rapidly absorbed from implantable sites via the capillaries and transferred to the systemic circulation, where it binds to plasma proteins; CDDP-derived platinum is more than 90 % protein-bound [23][24][25][26]. Therefore, the pharmacokinetics description of CDDP should include plasma total and free (unbound) platinum.…”

Section: Discussionmentioning

confidence: 99%

In vivo pharmacokinetic and tissue distribution investigation of sustained-release cisplatin implants in the normal esophageal submucosa of 12 beagle dogs

Yin

Wei

Juan

et al. 2015

Cancer Chemother Pharmacol

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

In vivo pharmacokinetic and tissue distribution investigation of sustained-release cisplatin implants in the normal esophageal submucosa of 12 beagle dogs

Yin

Wei

Juan

et al. 2015

Cancer Chemother Pharmacol

View full text Add to dashboard Cite

show abstract

“…Samples were handled and stored as described previously . Liquid chromatography with postcolumn derivatization was used to determine the concentration of cisplatin and to analyze the monohydrated complex of cisplatin, MHC . All samples were stored at −80°C until analysis, which occurred within 3 weeks.…”

Section: Methodsmentioning

confidence: 99%

Cochlear pharmacokinetics of cisplatin: An in vivo study in the guinea pig

et al. 2013

Self Cite

View full text Add to dashboard Cite

Objectives/Hypothesis: Cisplatin produces toxic lesions to outer hair cells (OHCs) in the cochlear base but not in the apex. The objective of this study was to compare the pharmacokinetic profile of cisplatin in scala tympani (ST) perilymph in the cochlear base and apex, respectively.Study Design: In vivo animal study. Methods: Forty-seven guinea pigs were given an intravenous bolus injection of an ototoxic dose of cisplatin. Ten to 240 minutes after cisplatin was given, blood, cerebrospinal fluid (CSF), and ST perilymph were aspirated within the same target time. ST perilymph was aspirated from the basal turn and from the apex of the cochlea by two different sampling techniques. Liquid chromatography with postcolumn derivatization was used for quantitative determination of the parent drug.Results: Ten minutes after administration, the concentration of cisplatin in ST perilymph was 4-fold higher in the basal turn of the cochlea than in the apex. At 30 minutes, the drug concentrations did not differ. At 60 minutes, the level of cisplatin in ST perilymph and blood UF was equivalent. The perilymph-blood ratio increased thereafter with time.Conclusion: The pharmacokinetic findings of an early high concentration of cisplatin in the base of the cochlea and delayed elimination of cisplatin from ST perilymph compared to blood might correlate to the cisplatin-induced loss of OHCs in the base of the cochlea.

show abstract

“…[4][5][6]. It is well known that cisplatin is partly hydrolyzed to a monohydrated complex (MHC) upon administration [7,8], and that both cisplatin and MHC undergo irreversible ligand exchange reactions with biological nucleophiles such as nucleotides, methionine, glutathione, and albumin [9,10]. Both cisplatin and MHC are responsible for the antitumor effects as well as the toxic side effects (e.g.…”

Section: Introductionmentioning

confidence: 99%

“…nephrotoxicity) [7,11]. After ligand exchange, the biotransformed platinum products are no longer biologically active [10,12].…”

Section: Introductionmentioning

confidence: 99%

“…Selective methods for the determination of cisplatin itself in biological matrices are based on HPLC followed by different kinds of on-line or off-line detectors such as radioactivity detection [27], UV detection [10,16,[28][29][30], flameless atomic absorption spectrometry (FAAS) [15], ICP-MS [31][32][33][34] and MS/MS [35]. UV-based methods usually require pre-column or post-column derivatization due to the low molar absorptivity of cisplatin in the UV spectrum [10,[28][29][30]36]. Pre-column derivatization is a sensitive, yet unselective approach because of the formation of the same derivatization product for cisplatin, MHC as well as other Pt-based complexes (e.g.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Zwitterionic hydrophilic interaction liquid chromatography-tandem mass spectrometry with HybridSPE-precipitation for the determination of intact cisplatin in human plasma

Xie

Colin

Bocxlaer

2017

Talanta

View full text Add to dashboard Cite

Cisplatin is a first-line chemotherapeutic for the treatment of a wide variety of cancers since its discovery in the 1960s. Although various techniques have been reported for the measurement of total platinum in biological matrices, such as inductively coupled plasma-mass spectrometry and derivatization procedures, a specific, sensitive and robust assay for the quantification of intact cisplatin is still lacking. Therefore, we present a rapid, selective, sensitive, and reliable UHPLC-MS/MS based method for the determination of intact cisplatin in human plasma in support of a Phase II clinical trial. The optimal chromatographic behavior of cisplatin was achieved on a Syncronis HILIC column (50 × 2.1mm, 1.7µm, zwitterionic stationary phase). The retention behavior of cisplatin on this zwitterion-based stationary phase was well described by an adsorptive interaction model. A simple sample preparation based on protein precipitation combined with the removal of phospholipids by HybridSPE-precipitation was developed. The method was proven to be free of a relative matrix effect. The assay was validated within a range of 20 - 10,000ng/mL using 100μL of plasma sample. The intra and inter-day precisions were all less than 7.6%, and none of the bias was greater than 13.1%, thus corroborating that the developed method is precise and accurate. As a proof of concept, the assay has been successfully applied to plasma samples obtained from different patients who were enrolled in the Phase II trial and were treated with cisplatin.

show abstract

Quantitative liquid chromatographic determination of intact cisplatin in blood with microwave-assisted post-column derivatization and UV detection

Cited by 14 publications

References 22 publications

In vivo pharmacokinetic and tissue distribution investigation of sustained-release cisplatin implants in the normal esophageal submucosa of 12 beagle dogs

In vivo pharmacokinetic and tissue distribution investigation of sustained-release cisplatin implants in the normal esophageal submucosa of 12 beagle dogs

Cochlear pharmacokinetics of cisplatin: An in vivo study in the guinea pig

Zwitterionic hydrophilic interaction liquid chromatography-tandem mass spectrometry with HybridSPE-precipitation for the determination of intact cisplatin in human plasma

Contact Info

Product

Resources

About